Physician profile
Yanming Xing
NPI 1154594737
$10,621.74
in general payments reported to CMS, 2019-2025
23 companies · $1,138 in 2025
The $1,138 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,967 · 2020: $1,105 · 2021: $1,912 · 2022: $1,654 · 2023: $1,740 · 2024: $1,106 · 2025: $1,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,746 · Education: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,746.49 |
| Education | $237.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,125.29 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $2,179.15 | 2019-2025 | Enbrel, Evenity, Otezla |
| Janssen Biotech, INC. | $1,434.74 | 2019-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $948.02 | 2019-2025 | |
| Glaxosmithkline, LLC. | $732.38 | 2019-2025 | Benlysta |
| Pfizer INC. | $390.67 | 2019-2024 | |
| Horizon Therapeutics Plc | $253.52 | 2019-2023 | Krystexxa |
| Radius Health, INC. | $215.82 | 2019-2025 | Tymlos |
| Lilly USA, LLC | $209.99 | 2019-2024 | Taltz |
| Astrazeneca Pharmaceuticals LP | $203.08 | 2022-2025 | Saphnelo, Enhertu |
| Ucb, INC. | $169.53 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $161.22 | 2019-2025 | Orencia |
| Celgene Corporation | $146.53 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.68 | 2019-2025 | Ofev, Cyltezo |
| Octapharma USA, INC. | $98.99 | 2022-2024 | Octagam Immune Globulin (Human) |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $58.03 | 2021 | |
| Sobi, INC | $46.97 | 2020-2022 | |
| Organon LLC | $21.79 | 2023 | Hadlima |
| Kiniksa Pharmaceuticals International, Plc | $19.13 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $18.15 | 2023 | Opsumit |
| Zyla Life Sciences, INC. | $17.76 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $16.72 | 2022 | |
| Sandoz INC. | $16.58 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yanming Xing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.